Dr. Weiss has more than three decades of clinical and scientific leadership and has dedicated his career to supporting the cancer community with clinically accurate testing and diagnostics. He received his BS summa cum laude and MD summa cum laude from the University of Maryland and completed a residency in Anatomic Pathology at the Brigham and Women’s Hospital, and a fellowship in Surgical Pathology at Stanford University Medical Center.

In addition to his corporate positions, Dr. Weiss previously served as Assistant Professor of Pathology at Stanford and President of the Medical Staff and Chairman of Pathology at the City of Hope. He is the author of over 500 papers and book chapters, and has authored or co-authored over a dozen books, including an AFIP Lymph Node Fascicle, Applied Immunohistochemistry, Lymph Nodes, and Knowles' Hematopathology. His laboratory discovered the first molecular evidence linking the Epstein-Barr virus with Hodgkin Lymphoma.

Dr. Weiss has won numerous awards, including the Benjamin Castleman, Arthur Purdy Stout, and the United States-Canadian Academy of Pathology Young Investigator Award, and has delivered more than 250 national and international talks in Pathology, including several named lectureships. He has been on the editorial board of over a dozen scientific journals and is a past President of the Los Angeles Society of Pathologists.

Dr. Huang has authored over 70 publications and research papers in the field of Hematopathology and possesses a KOL-level expertise in Leukemias. He previously served as Professor of Pathology & Director, Molecular Hematopathology and Bone Marrow/Lymph Node Pathology at Cedars-Sinai Medical Center in Los Angeles and as Director, Molecular Pathology at City of Hope National Medical Center in Duarte, CA.

Dr. Gao is the founder of the genetic testing business at Fulgent Genetics and is the lab director and chief scientific officer. Dr. Gao's prior experience includes service as Lab Director of both the DNA Sequencing Core Laboratory and Clinical Molecular Diagnostics Laboratory at City of Hope from 2004 until 2013. Dr. Gao completed his clinical molecular genetics training fellowship and post-doctoral fellowship at Harvard Medical School in 2004 prior to joining City of Hope.

Dr. Gao received an M.S. in Immunology and an M.D. from Peking University and Inner Mongolia University for Nationalities in China in 1993 and 1990, respectively, as well as a Ph.D. in Microbiology, Immunology and Medical Genetics from The Ohio State University in 2001. Dr. Gao is board certified in clinical molecular genetics by the American Board of Medical Genetics, is a Fellow of the American College of Medical Genetics and Genomics and serves as a team leader for laboratory inspections by CAP

Dr. Phillip Stafford has worked at commercial, non-profit, and academic institutions where he has leveraged his expertise in bioinformatics and precision oncology. In his current position, he manages a team of software engineers, bioinformatics scientists, and genetics scientists to support Fulgent's NGS and proteomic offerings.

Dr. Stafford's prior experience includes serving as vice president of bioinformatics at Caris Life Sciences, as professor of cancer immunology at the Biodesign Institute at Arizona State University, as director of bioinformatics at Translational Genomics Research Institute, and director of biostatistics at Motorola Life Sciences.

Dr. Stafford received three undergraduate degrees - in pathogenic microbiology, botany, and German - with minors in mathematics, chemistry, and physics from the University of Arkansas. He completed his PhD studies in the field of molecular pathogenesis and switching in the human pathogen at the University of Arkansas and completed post-doctoral work at Dartmouth Medical School and Woods Hole Marine Biological Laboratory. Dr. Stafford is a six Sigma blackbelt statistician, holds seven patents, and is the co-author of over 60 publications.

Dr. Kevin Goudy has extensive experience in creating next generation molecular and immunology assays and has patented several diagnostic methods and approaches including a method for the isolation of circulating tumor cells.

Prior to his work with Fulgent Oncology, Dr. Goudy held the position of Laboratory Director, Director of Research and Development at Pharmacogenetic Laboratories Technologies (PGXL) in Louisville, Kentucky where he was instrumental in developing both diagnostic assays for clinical testing and companion diagnostics for therapeutic monitoring. In addition to his commercial laboratory work, Dr. Goudy also served as a Clinical Assistant Professor for the Department of Pathology and Laboratory Medicine at the University of Louisville in Louisville, Kentucky.

Dr. Goudy received his Ph.D. in microbiology and immunology from the University of North Carolina in Chapel Hill, North Carolina. He completed a fellowship in clinical immunology at the University of North Carolina and at the San Raffaele Institute in Milan, Italy.